Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.

Publication Type:

Journal Article


Cancer, Volume 113, Issue 6, p.1370-8 (2008)


Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Child, Cytarabine, Daunorubicin, Disease-Free Survival, Female, Humans, Idarubicin, Leukemia, Myeloid, Acute, Male, Middle Aged, Remission Induction, Sarcoma, Myeloid, Survival Rate, Treatment Outcome


It is unknown whether patients with nonleukemic myeloid sarcoma (MS) and those with acute myeloid leukemia (AML) have similar responses to anti-AML treatment. In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes.